Workflow
Semtech(SMTC) - 2026 Q1 - Quarterly Report

Cash and Liquidity - As of April 27, 2025, the company's foreign subsidiaries held 136.1millionincashandcashequivalents,adecreasefrom136.1 million in cash and cash equivalents, a decrease from 139.1 million at January 26, 2025[181]. - The company expects future non-operating cash uses to be for capital expenditures and debt repayment, funded through cash flows from operating activities[183]. - On April 24, 2025, the company increased its total available borrowing capacity under the revolving credit facility by 117.5million,raisingthetotalfacilitysizeto117.5 million, raising the total facility size to 455.0 million[185]. - As of April 27, 2025, the company had 171.2millionoutstandingundertheTermLoansandnorevolvingloansoutstanding,withavailableundrawnborrowingcapacityof171.2 million outstanding under the Term Loans and no revolving loans outstanding, with available undrawn borrowing capacity of 452.1 million[187]. - The company issued 250.0millioninaggregateprincipalamountof2028NotesonOctober26,2023,bearinginterestat4.00250.0 million in aggregate principal amount of 2028 Notes on October 26, 2023, bearing interest at 4.00% per year, maturing on November 1, 2028[194]. - As of April 27, 2025, approximately 62.0 million of the 2028 Notes remained outstanding, with one condition for conversion met[195]. - The company is in compliance with the financial covenants in its Credit Agreement as of April 27, 2025[190]. - There have been no material changes to cash requirements from those disclosed in the Annual Report for the fiscal year ended January 26, 2025[203]. Operating Performance - In the first three months of fiscal year 2026, net cash provided by operating activities was 27,824thousand,asignificantincreasecomparedtoanetcashusedof27,824 thousand, a significant increase compared to a net cash used of 89 thousand in the same period of fiscal year 2025[204]. - Operating cash flows were positively impacted by a 21.8% increase in net sales, lower interest payments, and reduced restructuring payments, while negatively impacted by increased annual bonus payments and higher inventory spending[206]. - Capital expenditures for the first three months of fiscal year 2026 were 1.7million,upfrom1.7 million, up from 1.3 million in the same period of fiscal year 2025, reflecting investments in production capabilities[208]. - The company sold investments for proceeds of 0.5millioninthefirstthreemonthsoffiscalyear2026,comparedto0.5 million in the first three months of fiscal year 2026, compared to 2.7 million in the same period of fiscal year 2025[208]. - In the first three months of fiscal year 2026, the company made a prepayment of 10.0milliononitsTermLoans,withnosuchprepaymentsmadeinthesameperiodoffiscalyear2025[211].Employeesharebasedcompensationpayrolltaxespaidinthefirstthreemonthsoffiscalyear2026amountedto10.0 million on its Term Loans, with no such prepayments made in the same period of fiscal year 2025[211]. - Employee share-based compensation payroll taxes paid in the first three months of fiscal year 2026 amounted to 8.9 million, compared to 2.4millioninthesameperiodoffiscalyear2025[212].StrategicInitiativesThecompanyisconductingaportfoliorationalizationreviewtoidentifynoncoreassetsandalignitsportfoliowithitsstrategicvision[199].Thestockrepurchaseprogramwasexpandedbyanadditional2.4 million in the same period of fiscal year 2025[212]. Strategic Initiatives - The company is conducting a portfolio rationalization review to identify non-core assets and align its portfolio with its strategic vision[199]. - The stock repurchase program was expanded by an additional 350.0 million on March 11, 2021, allowing the company to repurchase its common stock at any time[200]. - The remaining authorization for share repurchase under the program as of April 27, 2025, was $209.4 million[201]. - Working capital fluctuates based on end-market demand and management of receivables, inventory, and payables, with potential acquisitions also impacting requirements[202]. - The company plans to finance significant expenditures for new product development through cash generated by operating activities and existing cash balances[198].